Appili Therapeutics Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
1.8M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Healthcare
Biotechnology
TSX
Key Financial Metrics
100,443
Revenue
-2.6M
Net Income
C$-0.02
EPS (Diluted)
866,456
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-190.0%
Net Profit Margin
-2613.1%
EBITDA
360,566
Returns & Efficiency
Return on Assets (ROA)
-86.5%
Return on Equity (ROE)
-
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
3.0M
Total Debt
12.3M
Debt to Equity
-
Current Ratio
0.19
Company Info
| Industry | Biotechnology |
| HQ | Halifax, Canada |
| Employees | 7 |
| Fiscal Year End | 1743379200 |
| Currency | CAD |
| Website | appilitherapeutics.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
237,200
Shares Sold
0
Total Transactions
1
SEDAR+ Filings
View All Filings4
Annual Reports
13
Quarterly Reports
14
MD&A
77
News Releases
9
Material Changes
2
Prospectuses
16
Governance
30
Certifications
58
Other
●
2023-06-23
●
2023-06-23
●
2022-06-29
●
2022-06-29
●
2019-09-19
●
2019-09-10
Interactive Charts
Company Profile
General Information
| Company Name | Appili Therapeutics Inc. |
| Ticker | APLI.TO |
| Exchange | TSX |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Halifax, Canada |
| Employees | 7 |
| Fiscal Year End | 1743379200 |
| Currency | CAD |
| Website | appilitherapeutics.com |
Financial Summary
| Market Cap | 1.8M |
| Revenue | 100,443 |
| Net Income | -2.6M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.02 |
| Net Margin | -2613.1% |
| ROE | N/A |
| Dividend Yield | N/A |
Business Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.